Doctored Fraud, Arrogance and Tragedy in the Quest to Cure Alzheimer's
-
- Englisch ausgewählt
11,99 €
UVP
15,00 €
inkl. gesetzl. MwSt.,
Lieferung nach Hause
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
09.04.2026
Verlag
Icon BooksSeitenzahl
320
Maße (L/B/H)
19/12,7/2,7 cm
Gewicht
284 g
Sprache
Englisch
ISBN
978-1-83773-261-6
*A FINANCIAL TIMES BOOK OF THE YEAR*
For readers of Empire of Pain and Dopesick, an arresting deep dive into how Alzheimer's disease treatment has been set back by corrupt researchers, negligent regulators, and the profit motives of Big Pharma.
Nearly seven million Americans live with Alzheimer's disease, a tragedy that is already projected to grow into a $1 trillion crisis by 2050. While families suffer and promises of pharmaceutical breakthroughs keep coming up short, investigative journalist Charles Piller's Doctored shows that we've quite likely been walking the wrong path to finding a cure all along - led astray by a cabal of self-interested researchers, government accomplices, and corporate greed.
Piller begins with a whistleblower - Vanderbilt professor Matthew Schrag - whose work exposed a massive scandal. Schrag found that a University of Minnesota lab led by a precocious young scientist and a renowned director delivered apparently falsified data at the heart of the leading hypothesis about the disease. Piller's revelations of Schrag's findings stunned the field and the public.
From there, based on years of investigative reporting, Doctored exposes a vast network of deceit and its players, all the way up to the FDA. Piller uncovers evidence that hundreds of important Alzheimer's research papers are based on false data. In the process, he reveals how even against a flood of money and influence, a determined cadre of scientific renegades have fought back to challenge the field's institutional powers in service to science and the tens of thousands of patients who have been drawn into trials to test dubious drugs. It is a shocking tale with huge ramifications not only for Alzheimer's disease, but for scientific research, funding, and oversight at large.
Kundinnen und Kunden meinen
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kund*innen durch Ihre Meinung
Kurze Frage zu unserer Seite
Vielen Dank für dein Feedback
Wir nutzen dein Feedback, um unsere Produktseiten zu verbessern. Bitte habe Verständnis, dass wir dir keine Rückmeldung geben können. Falls du Kontakt mit uns aufnehmen möchtest, kannst du dich aber gerne an unseren Kund*innenservice wenden.
zum Kundenservice